COL4A6 Antibody (G-2): sc-398655

COL4A6 Antibody (G-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects COL4A6 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-COL4A6 antibody (G-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. COL4A6 protein consists of 1,691 amino acids and serves as a crucial component of type IV collagen, a major structural element of the basement membrane. COL4A6 plays a vital role in providing structural support and regulating cell behavior, which is essential for maintaining tissue integrity and function. The basement membrane serves as a barrier and scaffold for cells, influencing processes such as filtration in kidneys and organization of tissues. Mutations in COL4A6 can lead to X-linked Alport syndrome, a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities, highlighting COL4A6′s importance in both health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

COL4A6 Antibody (G-2) References:

1. Absence of the alpha6(IV) chain of collagen type IV in Alport syndrome is related to a failure at the protein assembly level and does not result in diffuse leiomyomatosis.  |  Zheng, K., et al. 1999. Am J Pathol. 154: 1883-91. PMID: 10362815
2. Regulation of the paired type IV collagen genes COL4A5 and COL4A6. Role of the proximal promoter region.  |  Segal, Y., et al. 2001. J Biol Chem. 276: 11791-7. PMID: 11096082
3. Alport syndrome associated with diffuse leiomyomatosis: COL4A5-COL4A6 deletion associated with a mild form of Alport nephropathy.  |  Mothes, H., et al. 2002. Nephrol Dial Transplant. 17: 70-4. PMID: 11773466
4. Alport syndrome with diffuse leiomyomatosis.  |  Anker, MC., et al. 2003. Am J Med Genet A. 119A: 381-5. PMID: 12784310
5. Deletion mapping in Alport syndrome and Alport syndrome-diffuse leiomyomatosis reveals potential mechanisms of visceral smooth muscle overgrowth.  |  Thielen, BK., et al. 2003. Hum Mutat. 22: 419. PMID: 14517961
6. Bifunctional promoter of type IV collagen COL4A5 and COL4A6 genes regulates the expression of alpha5 and alpha6 chains in a distinct cell-specific fashion.  |  Sund, M., et al. 2005. Biochem J. 387: 755-61. PMID: 15598179
7. Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region.  |  Ikeda, K., et al. 2006. Am J Pathol. 168: 856-65. PMID: 16507901
8. Deletion of the 5'exons of COL4A6 is not needed for the development of diffuse leiomyomatosis in patients with Alport syndrome.  |  Sá, MJ., et al. 2013. J Med Genet. 50: 745-53. PMID: 23958657
9. COL4A6 is dispensable for autosomal recessive Alport syndrome.  |  Murata, T., et al. 2016. Sci Rep. 6: 29450. PMID: 27377778
10. Downregulation of Collagen COL4A6 Is Associated with Prostate Cancer Progression and Metastasis.  |  Ma, JB., et al. 2020. Genet Test Mol Biomarkers. 24: 399-408. PMID: 32551898
11. Lack of collagen α6(IV) chain in mice does not cause severe-to-profound hearing loss or cochlear malformation, a distinct phenotype from nonsyndromic hearing loss with COL4A6 missense mutation.  |  Tang, S., et al. 2021. PLoS One. 16: e0249909. PMID: 33848312
12. Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5.  |  Zhou, X., et al. 2021. Front Med (Lausanne). 8: 766224. PMID: 34778325

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-COL4A6 Antibody (G-2) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-COL4A6 Antibody (G-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

COL4A6 Antibody (G-2) Specifications

Alternate Product Name: COL4A6

Product Clone Name: G-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1323-1459

Epitope Target: COL4A6

Epitope Species: mouse

Product Reactivity/Detection: Collagen α6 Type IV

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for COL4A6 Antibody (G-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin